Lytix Biopharma ASA · OSL:LYTIX

Lytix Biopharma ASA — Q1 2025 Earnings Presentation

33 slides from Lytix Biopharma ASA's earnings presentation, May 15, 2025

  1. Slide 1: Developing the future of cancer treatment

    Developing the future of cancer treatment Fighting cancer by local killing of tumor cells and systemic activation of the immune system Q1 2025 results presentation 15.05.2025 1

  2. Slide 2: Disclaimer

    Disclaimer This presentation (the "Presentation") has been prepared by Lytix Biopharma AS ("Company") exclusively for information purposes. The Presentation is being made only to, and is only directed at, persons to whom such presentation may lawfully be communicated (’relevant persons’). Any person

  3. Slide 3: Presenting team

    Presenting team Øystein Rekdal, CEO Co-founder of Lytix Biopharma, Dr. Rekdal has served as CEO twice in Lytix, most recently since 2019. With a PhD in tumor immunology, his expertise in anticancer molecules from host defense peptides underpins Lytix's technology. He is a regular speaker at internat

  4. Slide 4: Company introduction

    Company introduction DC lytix

  5. Slide 5: Lytix Biopharma approaching commercialization

    Lytix Biopharma approaching commercialization Novel, unique and Robust portfolio of Strong phase II results in innovative technology clinical studies basal cell carcinoma Lytix technology already clinically proven Targeting different types of solid Led by licensing partner Verrica cancers Pharmaceut

  6. Slide 6: Lytix addresses major shortcomings in current cancer immunotherapy

    Lytix addresses major shortcomings in current cancer immunotherapy MALIGNANT MELANOMA CHALLENGE Majority of cancer patients lack active immune cells in the tumors and therefore don’t respond to current immunotherapy NON- RESPONDERS Lytix technology enhances the number of SOLUTION 60% 67% No/few immu

  7. Slide 7: Lytix's solution works through two phases

    Lytix’s solution works through two phases; killing tumors locally and activating a systemic broad immune response 7

  8. Slide 8: Q1 Highlights

    Q1 Highlights DC lytix

  9. Slide 9: Highlights for the first quarter (I/II)

    Highlights for the first quarter (I/II) - And post quarter end Verrica to report on FDA meeting and additional data from Phase II study in the coming period • Verrica remains on track and expects to report genomic and immune response data from the Phase 2 trial in mid- 2025 • Verrica is encouraged b

  10. Slide 10: Highlights for the first quarter (II/II)

    Highlights for the first quarter (II/II) - And post quarter end LTX-401 – Advancing towards the clinic with strengthened commercial and regulatory momentum • Clinical trial preparations underway, targeting start of Ph. I study in 2026 • Positive regulatory feedback supports Lytix clinical developmen

  11. Slide 11: Ramping up organization for commercialization

    Ramping up organization for commercialization Eric Falcand • 37+ years of intl. leadership and management experience in the (Chair) pharmaceutical industry • New board of directors elected at the General Meeting in April to NEW BOARD MEMBERS • Has led over 50 licensing and partnership agreements glo

  12. Slide 12: Words from the Chair

    Eric Falcand Words from the Chair

  13. Slide 13: Clinical and Operational update

    Clinical and Operational update

  14. Slide 14: Clinical progress

    Clinical progress Product candidate Study/partner Indication Discovery Phase I Phase II Phase III Melanoma patients progressed on checkpoint ATLAS-IT-05 inhibitors Phase II In combination with Keytruda® Verrica LTX-315 Basal cell carcinoma Phase II Phase III TBD H1 ‘25 Pharmaceuticals NeoLIPA Neoadj

  15. Slide 15: Phase II study: Basal cell carcinoma (Verrica Pharmaceuticals)

    Clinical and Operational update 1 Phase II study: Basal cell carcinoma (Verrica Pharmaceuticals)

  16. Slide 16: LTX-315: A potential paradigm shift in treatment of BCC

    Study: Verrica Ph. II Completed LTX-315: A potential paradigm shift in treatment of BCC BCCs typically found in skin exposed to sun ~80% located on the face and head Current treatment options are invasive ~95 % of BCC patients treated with surgery Before surgery After surgery Surgery can cause pain

  17. Slide 17: Phase II study: Late stage melanoma (ATLAS-IT-05)

    Clinical and Operational update 1 Phase II study: Late stage melanoma (ATLAS-IT-05)

  18. Slide 18: ATLAS-IT-05 (ongoing): Promising effects of LTX-315 in late-stage melanoma

    Study: ATLAS-IT-05 (ongoing): Promising effects of ATLAS-IT-05 Ongoing LTX-315 in heavily pre-treated patients with late-stage melanoma Complete regression in non-injected tumors Complete regression in injected tumors ! Positive interim data from Before Treatment 20 evaluable patients • Disease cont

  19. Slide 19: New phase II study: Earlier stage melanoma (NeoLIPA)

    Clinical and Operational update 1 New phase II study: Earlier stage melanoma (NeoLIPA)

  20. Slide 20: NeoLIPA – Expanding the potential of LTX-315

    Study: NeoLIPA Started NeoLIPA – Expanding the potential of LTX-315 Investigator Initiated Trial Study Overview • Evaluate LTX-315 in combination with pembrolizumab (PD-1 inhibitor), administered prior to surgery, in treatment naive patients with a robust immune system • Dual mode of action, in whic

  21. Slide 21: LTX-401

    Clinical and Operational update 1 LTX-401

  22. Slide 22: LTX-401 – a small oncolytic molecule with a large commercial potential

    LTX-401 – a small oncolytic molecule with a large commercial potential, including deep-seated cancer Small molecule LTX-401 approaching Similar mode-of-action as LTX-315 clinical stage with superior effects in liver cancer models • Partly validated by LTX- Significant commercial 315’s clinical resul

  23. Slide 23: Financials and outlook

    Financials and outlook DC lytix

  24. Slide 24: Key figures – profit and loss

    Key figures – profit and loss Amounts in NOK ‘000 Q1 2025 Q1 2024 FY 2024 Total operating income - 10,526 11,134 Total operating expenses (13,439) (29,212) (107,029) Loss from operations (13,439) (18,685) (95,896) Loss for the period (12,923) (18,183) (94,265) • As previously communicated, the decli

  25. Slide 25: Strengthened financial position going into 2025

    Strengthened financial position going into 2025 Total operating expenses Cash and short-term financial investments 34,209 130,791 32,998 117,903 100 218 22,537 23,280 21,540 78 767 19,581 20,009* 60 181 13,439 50 548 22,894 43 539 24,389 16,315 26 172 12,952 13,170 10,643 10,984* 6,266 Q2 23 Q3 23 Q

  26. Slide 26: Key figures – balance sheet

    Key figures – balance sheet Amounts in NOK ‘000 31.03.2025 31.03.2024 31.12.2024 Assets Property, plant and equipment 26 93 42 Right-of-use assets 2,807 213 2,589 Trade and other receivables 9,355 18,840 13,113 Short-term financial investments - 13,511 - Cash and cash equivalents 117,903 12,661 130,

  27. Slide 27: Lytix Biopharma's roadmap to create shareholder value

    Lytix Biopharma’s roadmap to create shareholder value Neoadjuvant melanoma Non-metastatic skin cancer and breast Deep seated cancer LTX-315: Clear path towards LTX-315: Phase II results in LTX-401: Phase I study in deep commercialization, demonstrated NeoLIPA seated tumors (2026) through licensing w

  28. Slide 28: Executing on our strategy – upcoming events

    Executing on our strategy – upcoming events Verrica - BCC ‒ Report immune response data (mid-2025) ‒ Global development program update, including the design of the Ph. III clinical program (mid-2025) Lytix Clinical Development ‒ Interim results from NeoLIPA (Q3 2025) ‒ Finalization of ATLAS-IT-05 st

  29. Slide 29: Q&A

    Q&A DC lytix

  30. Slide 30: Interim financial statements

    Interim financial statements

  31. Slide 31: Condensed interim statement of profit and loss

    Condensed interim statement of profit and loss Unaudited Unaudited Amounts in NOK thousands Q1 2025 Q1 2024 FY 2024 Revenue - 10,526 11,134 Other operating income - - - Total operating income - 10,526 11,134 Payroll and related expenses (4,105) (5,663) (22,590) Depreciation and amortization expenses

  32. Slide 32: Condensed interim statement of financial position

    Condensed interim statement of financial position Unaudited Unaudited Amounts in NOK thousands 31.03.2025 31.03.2024 31.12.2024 Assets Non-current assets Property, plant and equipment 26 93 42 Right-of-use assets 2,807 213 2,589 Total non-current assets 2,832 307 2,631 Current assets Trade and other

  33. Slide 33: Condensed interim statement of cash flows

    Condensed interim statement of cash flows Unaudited Unaudited Amounts in NOK thousands Q1 2025 Q1 2024 FY 2024 Cash flows from operating activities Loss for the period (12,923) (18,183) (94,265) Adjustments for: Depreciation of property, plant and equipment 17 17 68 Depreciation of right-of-use asse

Lytix Biopharma — Q1 2025 Earnings Presentation on 6ix